INTERIM REPORT FOR Q3 2022/23 - Seite 2

PRODUCT AND PIPELINE UPDATES

• North American 510(k) FDA clearance of Ambu’s next-generation Ambu aView 2 Advance endoscopy system. The system offers endoscopists compatibility with Ambu’s current and future endoscopes within pulmonology, urology and ENT. With the CE mark obtained in November 2022, Ambu completes the full global launch across all major markets.
• North American 510(k) FDA regulatory clearance of two smaller-sized bronchoscopes, completing Ambu’s fifth-generation bronchoscope portfolio. With the clearance, Ambu begins its commercialisation of the full Ambu aScope 5 Broncho offering in North America, while continuing its commercialisation in Europe, Australia and Japan.
• European regulatory clearance (CE mark) of Ambu VivaSight 2 SLT (single-lumen tube), completing Ambu’s one lung ventilation (OLV) portfolio.

 

OTHER HIGHLIGHTS

• Ambu has kickstarted new initiatives to strengthen profitability. In Anaesthesia and Patient Monitoring, Ambu will implement sizable price increases in selected low-margin areas, and globally, Ambu has started to exit ~40 countries to minimise complexity and zoom in on growth. This will potentially result in a revenue decline within Anaesthesia and Patient Monitoring in 2023/24.
• A new independent cystoscopy study showed that 7.1% of patients treated with a reusable cystoscope returned for an unplanned post-procedure encounter, while the same was the case for only 2.2% of patients treated with a single-use cystoscope.
• A recently published study within GI concluded that the shift from reusable to single-use gastroscopes potentially increases reimbursement revenues in excess of $800K annually.
• Ambu renewed its partnership agreement with Plastic Bank, thus continuing its commitment to counterbalancing the plastic present in all of its single-use endoscopes across EMEA and Latin America.
• On 1 August 2023, Finn Möhring joined Ambu as part of the Executive Leadership Team and Chief Technology Officer, heading up Ambu’s R&D organisation.

 

Q3 2022/23 CONFERENCE CALL
A conference call is scheduled for 31 Aug 2023, at 09:00-10:00 (CEST). The conference is broadcast live via Ambu.com/webcastQ32023.

To ask questions during the Q&A session, please register prior to the call via Ambu.com//conferencecallQ32023register.

Upon registration, you will receive dedicated dial-in details via e-mail to access the call, including a passcode, a unique PIN, dial-in numbers and a calendar invitation.